A small study tested a medication called secukinumab for adults with active Graves orbitopathy. This condition affects the eyes and tissues around them, but the trial size was very limited. The study included only twenty-eight adults with moderate to severe symptoms that were not threatening sight. It was a multicenter trial comparing the drug against a placebo injection over a sixteen week period.
Participants received either the medication or a placebo injection twice. After sixteen weeks, none of the patients showed an overall response. There were no meaningful changes in eye symptoms, measurements, or quality of life compared to the placebo group. Results remained the same after thirty-two weeks. Thyroid hormone levels also did not change significantly. Eye muscle movement and lid opening stayed stable without improvement.
The drug was generally well tolerated with mostly mild side effects. Neither treatment caused study discontinuations or new safety signals. However, the small number of participants means these results need more research to be certain. Patients should discuss current treatment options with their doctors rather than expecting this new therapy to work.